Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

2024 Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

The Relapsed and Refractory MM Patient: When Immune Approaches Are I…

Joseph Mikhael

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

Standards of Care and Future Directions in FL

Martin Dreyling

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

New Updates in Frontline DLBCL

Scripps Health

L. Nastoupil

Polatuzumab Vedotin for 1L DLBCL: Results From the POLARIX Trial

Wojciech Jurczak

Treatment Landscape in 1L DLBCL: Polatuzumab Vedotin as SoC

Georg Lenz

Current Management of DLBCL From Frontline to Relapsed Disease

Dipenkumar Modi

Debates in CLL: Measuring MRD is NOT the SOC

UChicago Medicine

J. Soumerai

Practice-Changing Updates in DLBCL and HL

Massachusetts General Hospital Cancer Center

J. Erika Haydu

Hematopathology Tumor Board: Case Studies and Diagnostic Challenges …

UChicago Medicine

G. Venkataraman, A. Perry, K. Cahill, A. Akmatbekov, L. Wu

Polatuzumab Vedotin in 1L DLBCL: Perspectives on the POLARIX Trial

Juan Pablo Alderuccio

Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

What's Current in Immunotherapy in DLBCL and FL

Houston Methodist

A. Mehta

Frontline DLBCL Treatment Approaches

MyCancerHaven

R. Vij, H. Cherng

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

Tara Graff